Ana Cuesta Fernandez, MD
Hematology & Oncology · Orlando, FLNPI 1841506854
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,165 of the $39,584 with a category attached, or 61.0%. Pfizer accounts for 76.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $27,120 and has fallen 71.2% since, to $7,807 in 2025.
Across 54 payments — averaging $733.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$30K
- AstraZeneca$6K
- Novartis$3K
- Daiichi Sankyo Inc.$284
- Bayer$51
- Genentech, Inc.$32
- plus $193 from 9 others
Across 212 payments — averaging $31,938 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.9M
- Seagen Inc.$1.3M
- Genentech, Inc.$194K
- Merck$187K
- Pfizer$74K
- Astrazeneca UK Limited$51K
- plus $25K from 3 others
What the payments were for
- Consulting fees$11,59429%
- Speaking & faculty fees$24,16561%
- Travel & lodging$2,5736%
- Food & beverage$1,2413%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $30,251 |
| AstraZeneca | 10 | $6,187 |
| Novartis | 7 | $2,586 |
| Daiichi Sankyo Inc. | 10 | $284 |
| Bayer | 2 | $51 |
| Genentech, Inc. | 1 | $32 |
| Stryker | 1 | $31 |
| GSK | 2 | $28 |
| Macrogenics, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,584 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 149 | $2,209,869 |
| KisqaliRibociclib Succinate | 64 | $939,693 |
| EliquisApixaban | 24 | $24,843 |
| Anastrozole | 630 | $12,365 |
| Exemestane | 57 | $10,560 |
| Letrozole | 177 | $4,490 |
| Ondansetron Hcl | 34 | $658 |
| Tamoxifen Citrate | 17 | $610 |
| Prochlorperazine Maleate | 46 | $535 |
| Alendronate Sodium | 37 | $262 |
| Gabapentin | 25 | $253 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $221 |
| Temazepam | 11 | $212 |
| Olanzapine | 11 | $80 |
| Prednisone | 20 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $30,251 | $2,234,713173 claims |
| NovartisKisqali | $2,586 | $939,69364 claims |
| Lilly USA, LLCOlanzapine | $20 | $8011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Orlando
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Daniel LandauOrlando$1.8M
- Shahram MoriOrlando$952K
- Sajeve ThomasOrlando$639K
- Nikita ShahOrlando$470K
- Martin DietrichRockledge$6.2M
- Edgardo SantosFort Lauderdale$2M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.